Study M1106
Study name | Zou XS 2022 |
Title | Compound Gaoziban tablet alleviates depression via toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-kappa B pathway |
Overall design | The aim of this study was to explore the underlying mechanism of antidepressant effect of Compound Gaoziban tablet in the chronic unpredictable mild stress (CUMS) model of depression. Sprague-Dawley rats were divided into the following 5 groups (n = 12 in each group): (1) control group, (2) CUMS group, (3) CUMS + middle dose of Compound Gaoziban tablet group (stressor plus Compound Gaoziban tablet treatment at the dose of 0.8 g/kg), (4) CUMS + high dose of Compound Gaoziban tablet group (stressor plus Compound Gaoziban tablet treatment at the dose of 1.6 g/kg), and (5) CUMS + fluoxetine group (stressor plus fluoxetine treatment at the dose of 3.69 mg/kg). The CUMS stress procedure lasted for 6 weeks, and drugs were administered during the last 2 weeks of the model building period. Neurotransmitters of hippocampus were detected by liquid chromatography-mass spectrometry. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Rat; Sprague-Dawley rat; |
Categories of depression | Animal model; Chronic mild stress model; Chronic mild stress model; |
Criteria for depression | Sucrose preference test, forced swimming test |
Sample size | 60 |
Tissue | Central; Brain; Hippocampus; |
Platform | MS-based; LC-MS: ultraperformance liquid chromatograph (Shimadu, Japan) with tandem 4500 AB Sciex triple quadrupole mass spectrometer (AB Sciex, Boston, MA, USA); |
PMID | |
DOI | |
Citation | Zou X, Shi L, Yin H, et al. Compound Gaoziban tablet alleviates depression toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-kappa B pathway. J Tradit Chin Med. 2022 Dec;42(6):956-964. |
Metabolite |
